Eli Lilly (LLY) has emerged as a surprising growth leader, primarily driven by its dominance in the U.S. GLP-1 obesity drug market, where it controls about 60% of the share, surpassing Novo Nordisk. This strong market position has translated into significant revenue growth, with Lilly’s stock soaring over 160% in the past three years. Recently, shares have surpassed the $1,000 mark, raising speculation about a potential stock split, which could make the stock more accessible to a broader range of investors.
The implications of a stock split are multifaceted. While it does not alter the fundamental value of the company, it can lower the per-share price, attracting retail investors who might find high prices prohibitive. Additionally, a split could signal management’s confidence in continued growth, especially as Lilly expands its portfolio with new oral obesity medications, which are gaining traction in the market.
For market professionals, the key takeaway is that if Lilly maintains its stock price above $1,000, the company may consider a split in 2026. This could further enhance liquidity and investor interest, particularly among smaller investors looking to enter the stock.
Source: fool.com